Par Drugs & Chemicals Ltd

Par Drugs & Chemicals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 March 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 March 2026, providing investors with the latest insights into its performance and outlook.

Par Drugs & Chemicals Ltd is rated Sell by MarketsMOJO, with this rating last updated on 02 March 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Par Drugs & Chemicals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 18 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 February 2026, providing investors with the latest insights into its performance and outlook.

Par Drugs & Chemicals Ltd has witnessed a notable shift in its valuation parameters, moving from a very attractive to an attractive rating, driven primarily by its current price-to-earnings (P/E) and price-to-book value (P/BV) ratios. Despite a challenging recent performance relative to the Sensex, the stock’s improved valuation metrics and solid return on capital employed (ROCE) suggest a nuanced investment case for market participants.

Par Drugs and Chemicals Ltd., a micro-cap chemical manufacturer with a market capitalisation of ₹124.83 crores, delivered a robust quarterly performance in Q3 FY26, posting net profit of ₹4.80 crores—a sharp 16.23% quarter-on-quarter increase and a remarkable 727.59% year-on-year surge. However, this impressive quarterly snapshot conceals deeper structural concerns that have plagued the company's long-term trajectory, with the stock down 41.57% over the past year despite the recent operational uptick.

Par Drugs & Chemicals Ltd has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade, reflecting evolving market perceptions and sector dynamics. Despite a recent 5.2% intraday price gain, the stock’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a more cautious outlook compared to its historical benchmarks and peer group averages.

Par Drugs & Chemicals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 10 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 February 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Par Drugs & Chemicals Ltd has seen a notable shift in its valuation parameters, moving from an attractive to a fair rating as of early 2026. This change reflects evolving market perceptions amid subdued price performance and relative sector dynamics, prompting investors to reassess the stock’s price attractiveness compared to historical and peer benchmarks.

Par Drugs & Chemicals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 10 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 29 January 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Par Drugs & Chemicals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 10 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Par Drugs & Chemicals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 10 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 December 2025, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Par Drugs & Che., a microcap player in the Chemicals & Petrochemicals sector, has experienced a revision in its market evaluation reflecting nuanced shifts across key analytical parameters. This development comes amid a volatile performance trajectory and evolving market conditions.

Par Drugs and Chemicals Ltd., a micro-cap speciality chemicals manufacturer based in Gujarat, reported a sequential profit recovery in Q2 FY26, with net profit climbing to ₹4.13 crores from ₹3.33 crores in the previous quarter. However, the year-on-year comparison reveals a more sobering reality: profits plunged 51.98% from ₹8.60 crores in Q2 FY25, whilst the company's stock has witnessed a brutal correction, trading at ₹93.70—down 73.11% from its 52-week high of ₹348.45.